Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Phenotype Changes and Personalized Treatment in CRPC
NCT02208583Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gefitinib, vemurafenib, celecoxib oral solution, lapatinib, sunitinib and 1 more in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Molecular phenotypic changes after acquired resistance of hormonal therapy at 24 months and clinical progression free survival at 24 months. Status: unknown.
02
Drugs
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02208583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208583.